Autres langues Biomm S.A.

Actions

BIOM3

BRBIOMACNOR2

Marché Fermé - Sao Paulo Autres places de cotation 22:11:00 06/06/2024			Varia. 5j.	Varia. 1 janv.
16,4 ^BRL	+0,24 %		-6,29 %	+183,74 %

16/05	Biomm S.A. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
17/04	Biocon Limited signe un accord exclusif de licence et de fourniture avec Biomm S.A.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05
Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	18/04
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	17/04
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Biomm S A : Webcast Presentation 3Q23	14/11
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23
Biomm S A : Apresentação de resultados 2T23	10/08/23
Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, A Stelara Biosimilar	16/06/23
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23/03/23
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23/03/23
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/11/22
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22
Biomm S A : Presentation of 1Q22 Results	16/05/22
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	14/05/22
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	25/03/22
Biomm S A : Comunicado ao Mercado	03/03/22
Lupin Enters Partnership to Market Biosimilar Pegfilgrastim in Brazil	06/12/21
CytoDyn : Receives Clearance from Brazil's FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)	23/09/21

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Biomm S.A.

Actions

BIOM3

BRBIOMACNOR2

Autres langues

Filtres